Month: June 2022

In this photo illustration the Food and Drug Administration (FDA) and Novavax logos are seen behind a medical syringe and vials. Pavlo Gonchar | LightRocket | Getty Images Novavax’s Covid-19 vaccine will face the scrutiny of the Food and Drug Administration’s independent immunization experts this week, a crucial step on the path toward U.S. regulatory
0 Comments
Several persistent yet nonspecific symptoms have been reported in individuals who have previously recovered from infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This phenomenon has been referred to as long coronavirus disease 2019 (COVID-19), post-COVID syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). Although no viral load is detected in these patients,
0 Comments
WASHINGTON — Prior authorization, that oft-maligned process of getting insurer approval prior to performing a procedure or prescribing a drug, is in the spotlight once again, on several fronts. On Capitol Hill, the issue began to bubble up in late April, when the Department of Health and Human Services (HHS) Office of Inspector General (OIG)
0 Comments
NEW ORLEANS ­— Two patients with type 1 diabetes have now experienced improved blood glucose control with Vertex Pharmaceutical’s investigational allogeneic stem-cell derived islets (VX-880), with the first person now completely insulin-independent at 9 months post-transplant. Prior to the procedure, both patients had hypoglycemic unawareness and had experienced multiple episodes of severe hypoglycemia, conditions considered
0 Comments
Arsani William, a second-year student at Harvard Medical School, hopes to build a career that will impact an entire population. He believes that interactions with fellow students and professors at HMS will help him navigate that route. Learn more about William at http://hms.harvard.edu/news/case-study-camaraderie-1-28-13 and the Program in Medical Education at http://hms.harvard.edu/departments/medical-education
0 Comments
Working the night shift can be particularly arduous and even dangerous for workers like doctors and nurses. They need to take 20-minute power naps, according to an expert who will discuss such naps’ importance for the safety of health workers and their patients. Sleep isn’t just a time of rest as it is an “essential“ part of people’s overall
0 Comments
High-dose ifosfamide has shown superior survival benefit over three other chemotherapy regimens for patients with recurring or refractory primary Ewing sarcoma (RR-ES) in the practice-changing rEECur trial. This international trial is the first randomized head-to-head comparison of commonly used chemotherapy regimens in patients with the rare and deadly disease. The study results are expected to
0 Comments
7 Low-Carb Breakfast Recipes to Start Your Day – Diabetes Daily Learning Center Learning Center: LearningCenter Diabetes Daily does not provide medical advice,diagnosis or treatment.Get additional information.© 2005 – 2022 Everyday Health, Inc. Everyday Health is among the federally registered trademarks of Everyday Health, Inc. and may not be used by third parties without explicit
0 Comments
Test tubes labelled “Monkeypox virus positive and negative” are seen in this illustration taken May 23, 2022.  Dado Ruvic | Reuters The Biden administration has distributed 1,200 monkeypox vaccine doses for people who have had high-risk exposures to the virus, part of a nationwide public health response to stamp out the disease before it causes
0 Comments
CHARLOTTE, N.C. — Positive airway pressure (PAP) machines were helpful enough that pediatric patients could have symptoms improve even without being compliant, according to researchers advocating for greater access to this therapy for this population. At one center’s sleep clinic, 172 out of 221 children with obstructive sleep apnea (OSA) reported improved symptoms approximately 3
0 Comments
New results from a trial in patients with newly diagnosed multiple myeloma offer some answers to questions about which treatment route to choose. The trial, known as DETERMINATION, found that newly diagnosed patients treated with a triplet of drugs had longer progression-free survival (PFS) if they received an autologous stem cell transplant (ASCT) soon after
0 Comments
Aqueous droplet formation by liquid-liquid phase separation (or coacervation) in macromolecules is a hot topic in life sciences research. Of these various macromolecules that form droplets, DNA is quite interesting because it is predictable and programmable, which are qualities useful in nanotechnology. Recently, the programmability of DNA was used to construct and regulate DNA droplets
0 Comments
The investigational insulin-only iLet Bionic Pancreas (Beta Bionics) reduced A1c without increasing hypoglycemia in adults and children with type 1 diabetes with greater automation than currently available hybrid closed-loop or artificial pancreas insulin delivery systems. Results from the pivotal multicenter Insulin-Only Bionic Pancreas Pivotal Trial were presented during a 1-hour symposium on June 3 at
0 Comments
Researchers at Baylor College of Medicine and Texas Children’s Hospital have identified potent, highly specific compounds that interfere with bromodomain (BD)-containing proteins involved in cancer. The compounds, called BET BD1-inhibitors, are a starting point in the development of potentially more effective anti-cancer drugs with less side effects. The team reports in the Proceedings of the
0 Comments
CHICAGO — Randomized data suggest that an anti-angiogenic agent can kick-start immunotherapy’s antitumor activity in non-small cell lung cancer (NSCLC) patients whose disease has already progressed after chemotherapy and a checkpoint inhibitor. In the phase II study, median overall survival improved by nearly 3 months with ramucirumab (Cyramza) plus pembrolizumab (Keytruda) versus standard-of-care options (14.5
0 Comments
Treatment of people with obesity but no diabetes with the dual incretin agonist tirzepatide safely produced “unprecedented” levels of weight loss in the vast majority of patients in SURMOUNT-1, a placebo-controlled trial with more than 2500 people with obesity or overweight plus at least one weight-related complication. Although the pivotal trial did not directly compare
0 Comments
In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial’s prespecified level for statistical significance. Improvement
0 Comments